viropharma - 500 Beiträge pro Seite
eröffnet am 08.08.00 01:24:30 von
neuester Beitrag 29.08.00 16:40:50 von
neuester Beitrag 29.08.00 16:40:50 von
Beiträge: 6
ID: 207.561
ID: 207.561
Aufrufe heute: 0
Gesamt: 1.398
Gesamt: 1.398
Aktive User: 0
ISIN: US9282411084 · WKN: 903906
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 38,27 | +28,16 | |
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 3,6100 | +17,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Feedback
Viropharma-News:
Als Board Information gedacht.
Viel Spass bei der Lektüre.
Gute Nacht
durt
VIROPHARMA INC
Filed on Aug 7 2000
MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Our disclosure and analysis in this report contains some forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to present or anticipated scientific or regulatory progress, development of potential pharmaceutical products, future revenues, capital expenditures, research and development expenditures, future financings and collaborations, personnel, manufacturing requirements and capabilities, and other statements regarding matters that are not historical facts or statements of current condition.
Any or all of our forward-looking statements in this report may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors, including those mentioned in the discussion below and those described in the "Risk Factors" discussion of our most recent registration statement on From S-3 filed with the Securities and Exchange Commission, will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially. We do not intend to update our forward- looking statements to reflect future events or developments.
Since inception, the Company has devoted substantially all of its resources to its research and product development programs. ViroPharma has generated no revenues from product sales and has been dependent upon funding primarily from equity and debt financing. The Company does not expect any revenues from product sales for at least the next two years. The Company has not been profitable since inception and has incurred a cumulative net loss of $90,080,172 through June 30, 2000. Losses have resulted principally from costs incurred in research and development activities and general and administrative expenses. The Company expects to incur additional operating losses over at least the next several years. The Company expects such losses to increase over historical levels, primarily due to expected increases in the Company`s research and development expenses, further clinical trials of the Company`s most advanced drug candidate, pleconaril (including any significant additional studies for approval in the European Union, if any are required), and milestone payments that may be payable under the terms of the Company`s Agreement with Sanofi-Synthelabo in respect of pleconaril. Also, the Company expects to incur expenses related to its marketing and market research activities for pleconaril, its development of a marketing and sales staff and further research and development related to its hepatitis C and RSV disease product candidates. The Company`s ability to achieve profitability is dependent on developing and obtaining regulatory approvals for its product candidates, successfully commercializing such product candidates (which may include entering into collaborative agreements for product development and commercialization), and securing contract manufacturing services and distribution and logistics services.
Liquidity and Capital Resources
The Company commenced operations in December 1994. The Company is a development stage company and to date has not generated revenues from product sales. The cash flows used in operations are primarily for research and development activities and the supporting general and administrative expenses. Through June 30, 2000, the Company has used approximately $79.5 million in operating activities. The Company invests its cash in short-term investments. Through June 30, 2000, the Company has used approximately $230.0 million in investing activities, including $224.1 million in short-term investments and $5.9 million in equipment purchases and new construction. Through June 30, 2000, the Company has financed its operations primarily through public offerings of common stock, a convertible subordinated notes offering, private placements of redeemable preferred stock, two bank loans, equipment lease lines and a milestone advance totaling approximately $311.6 million. At June 30, 2000, the Company had cash and cash equivalents and short-term investments aggregating approximately $226 million.
We lease our corporate and research and development facilities under an operating lease expiring in 2008. We also have the right to expand the facility and, under certain circumstances, to purchase the facility. We have exercised our right to expand our current facility by 22,500 square feet. We will incur no additional material capital expenditures in connection with this expansion. We expect that rent expense in future years will increase approximately $268,000 per year, commencing in late-2000. We have financed substantially all of our equipment under two bank loans and two master lease
agreements. The first bank loan, which we entered into in February 1997, is for $600,000, is payable in equal monthly installments over 72 months and has a 9.06% interest rate. The second bank loan, which we entered into in December 1998, is for $500,000, is payable in equal monthly installments over 60 months and has a 7.25% interest rate. We have paid off both of the lease agreements. As of July 1, 2000, aggregate outstanding borrowings under these bank loans were approximately $625,000.
Under our agreement with Sanofi-Synthelabo, we are required to make milestone payments upon the achievement of certain development milestones and, until the expiration of the last patent on pleconaril or any related drug, royalty payments on any sales in the United States and Canada of products developed under the agreement. The development milestones include regulatory submissions of New Drug Applications and regulatory approvals in various jurisdictions, however, we may not be able to achieve these milestones. Unless the agreement is earlier terminated, in September 2001 or within 60 days after we file a New Drug Application for pleconaril (whichever occurs sooner), we will be required to pay Sanofi-Synthelabo $900,000.
We entered into an addendum to our development agreement with SELOC France in 1998. Under this addendum, SELOC France has manufactured three validation batches of pleconaril drug substance. We will pay approximately $1,000,000 during the second half of 2000 under this addendum. SELOC France is also assisting us in preparing the pleconaril drug master file and is preparing certain documentation that will be required with our New Drug Applications for pleconaril.
On October 9, 1997, the Company received $1,000,000 from Boehringer Ingelheim Pharmaceuticals, Inc. ("BI") as an advance on a future milestone in connection with a Collaborative Research Agreement (the "Agreement"). The Agreement expired in August 1998. Such amount is due and payable in August 2000. The loan bears interest at 8.5% and is evidenced by a convertible promissory note. If amounts due under the note are not paid as described in the note, BI may convert the then outstanding principal balance and accrued interest thereon into shares of the Company`s common stock based on the last sale price of such common stock on the date immediately prior to the date on which the Company is notified of BI`s intention to convert the promissory note.
We have incurred losses from operations since inception. We expect to incur additional operating losses over at least the next several years. We expect to incur such losses at an increasing rate over at least the next several years primarily due to expected increases in our research and development expenses, further clinical trials and clinical development of our most advanced product candidate, pleconaril (including any significant additional studies for approval in the European Union, if any are required), and milestone payments that may be payable under the terms of our agreement with Sanofi-Synthelabo for pleconaril. Specifically, we expect to increase spending over historical levels for at least the next nine months as we conduct two pivotal clinical trials and several supporting studies for the use of pleconaril for the treatment of viral respiratory infection. Also, we expect to incur expenses for pleconaril marketing and market research activities, our development of a marketing and sales staff and building the requisite infrastructure, and further research and development related to our hepatitis C and RSV disease product candidates. We expect to increase spending over historical levels for at least the next nine months for our hepatitis C and RSV disease product candidates in connection with an anticipated exploratory clinical trial with VP50406 for the treatment of Hepatitis C and the anticipated initiation of safety studies with VP14637 for the treatment of RSV pneumonia. We expect that our spending in the general and administrative areas to remain relatively constant over at least the next six to nine months with such spending in the first half of 2000.
We expect that we will need to raise additional funds to continue our business activities and to further expand our facilities. We may need additional financing to complete all clinical studies, to develop our marketing and sales staffs for pleconaril and to build the requisite infrastructure. We expect that we will need additional financing for the development and required testing of our hepatitis C and RSV disease compounds, and for any other product candidates. To obtain this financing, we intend to access the public or private equity or debt markets or enter into additional arrangements with corporate collaborators to whom we may issue shares of our stock. For example, in connection with our collaboration and license agreement, American Home Products Corporation will purchase our common stock at a market value premium at the time of completion of certain product development stages. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may dilute the ownership of existing stockholders. Collaborative arrangements may require us to grant product development programs or licenses to third parties for products that we might otherwise seek to develop or commercialize ourselves. Additional financing, however, may not be available on acceptable terms from any source. If sufficient additional financing is not available, we may need to delay, reduce or eliminate current research and development programs or other aspects of our business.
Results of Operations
Quarters ended June 30, 2000 and 1999
We earned license fee revenue from our collaboration with Wyeth-Ayerst in the hepatitis C area of $250,000 for the quarter ended June 30, 2000. We had no revenues for the quarter ended June 30, 1999. Research and development expenses decreased to $4,267,971 for the quarter ended June 30, 2000 from $5,233,702 for the quarter ended June 30, 1999. In the second quarter of 2000, the company was preparing to initiate two pivotal trials with pleconaril, the company`s most advanced drug candidate, for the treatment of viral respiratory infection, conducting safety studies with VP50406 for hepatitis C and conducting additional preclinical studies with VP14637 for RSV disease. In the second quarter of 1999, the company was conducting two clinical trials with pleconaril and advancing both the hepatitis C and RSV disease programs. The decrease in expenses in the second quarter of 2000 was primarily due to the fact that clinical studies for pleconaril were ongoing in the second quarter of 1999, and no such studies were conducted in the same period of 2000. Also, the offsetting credit to the receivable due from Wyeth-Ayerst in connection with our hepatitis C collaboration of approximately $1,275,000 has been recorded as a credit to research and development expenses. General and administrative expenses increased to $2,052,367 for the quarter ended June 30, 2000 from $1,240,116 for the quarter ended June 30, 1999. The increase was principally due to an increase in employee related expenses and business development related activities. Interest expense and interest income increased substantially in the second quarter of 2000 compared to the second quarter of 1999. The increases are due to the investing of $180 million convertible subordinated debentures issued in March of 2000 which pay 6% interest per annum. Also, currently the weighted average interest rate that we are earning on our investments is 6.1%. The net loss decreased to $5,389,244 for the quarter ended June 30, 2000 from $6,104,776 for the quarter ended June 30, 1999.
Six-months ended June 30, 2000 and 1999
We earned license fee and milestone revenue from our collaboration with Wyeth-Ayerst in the hepatitis C area of $1,500,000 for the six-month period ended June 30, 2000. We had no revenues for the six-month period ended June 30, 1999. Research and development expenses increased to $10,839,704 for the six- month period ended June 30, 2000 from $10,094,585 for the six-month period ended June 30, 1999. The increase was principally due to the completion of three phase 3 clinical trials of pleconaril, conduct of phase 1 clinical trials of VP50406 for the treatment of hepatitis C and the advancement of our drug candidate for the treatment of RSV disease. Also, the offsetting credit to the receivable due from Wyeth-Ayerst in connection with our hepatitis C collaboration of approximately $1,275,000 has been recorded as a credit to research and development expenses. General and administrative expenses increased to $4,161,500 for the six-month period ended June 30, 2000 from $2,394,332 for the same period of 1999. The increase was principally due to an increase in employee related expenses, pre-marketing expenses related to pleconaril and business development related activities. Interest expense and interest income increased substantially in the six-month period ended June 30, 2000 compared to the same period in 1999. The increases are due to the investing of $180 million convertible subordinated debentures issued in March of 2000 which pay 6% interest per annum. Also, currently the weighted average interest rate that we are earning on our investments is 6.1%. The net loss increased to $12,159,172 for the six-month period ended June 30, 2000 from $11,769,403 for the six-month period ended June 30, 1999.
Recently Issued Accounting Standards
In December 1999, the staff of the Securities and Exchange Commission issued Staff Accounting Bulleting ("SAB") No. 101, Revenue Recognition in Financial Statements ("SAB 101"). SAB 101 summarizes certain of the staff`s views in applying generally accepted accounting principles to revenue recognition in financial statements, including the recognition of non-refundable fees received upon entering into arrangements. We are in the process of evaluating this SAB and the effect it will have on our financial statements and current revenue recognition policy.
--------------------------------------------------------------------------------
© Copyright 1995-1999 EDGAR Online, Inc. All rights reserved.
Als Board Information gedacht.
Viel Spass bei der Lektüre.
Gute Nacht
durt
VIROPHARMA INC
Filed on Aug 7 2000
MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Our disclosure and analysis in this report contains some forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to present or anticipated scientific or regulatory progress, development of potential pharmaceutical products, future revenues, capital expenditures, research and development expenditures, future financings and collaborations, personnel, manufacturing requirements and capabilities, and other statements regarding matters that are not historical facts or statements of current condition.
Any or all of our forward-looking statements in this report may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors, including those mentioned in the discussion below and those described in the "Risk Factors" discussion of our most recent registration statement on From S-3 filed with the Securities and Exchange Commission, will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially. We do not intend to update our forward- looking statements to reflect future events or developments.
Since inception, the Company has devoted substantially all of its resources to its research and product development programs. ViroPharma has generated no revenues from product sales and has been dependent upon funding primarily from equity and debt financing. The Company does not expect any revenues from product sales for at least the next two years. The Company has not been profitable since inception and has incurred a cumulative net loss of $90,080,172 through June 30, 2000. Losses have resulted principally from costs incurred in research and development activities and general and administrative expenses. The Company expects to incur additional operating losses over at least the next several years. The Company expects such losses to increase over historical levels, primarily due to expected increases in the Company`s research and development expenses, further clinical trials of the Company`s most advanced drug candidate, pleconaril (including any significant additional studies for approval in the European Union, if any are required), and milestone payments that may be payable under the terms of the Company`s Agreement with Sanofi-Synthelabo in respect of pleconaril. Also, the Company expects to incur expenses related to its marketing and market research activities for pleconaril, its development of a marketing and sales staff and further research and development related to its hepatitis C and RSV disease product candidates. The Company`s ability to achieve profitability is dependent on developing and obtaining regulatory approvals for its product candidates, successfully commercializing such product candidates (which may include entering into collaborative agreements for product development and commercialization), and securing contract manufacturing services and distribution and logistics services.
Liquidity and Capital Resources
The Company commenced operations in December 1994. The Company is a development stage company and to date has not generated revenues from product sales. The cash flows used in operations are primarily for research and development activities and the supporting general and administrative expenses. Through June 30, 2000, the Company has used approximately $79.5 million in operating activities. The Company invests its cash in short-term investments. Through June 30, 2000, the Company has used approximately $230.0 million in investing activities, including $224.1 million in short-term investments and $5.9 million in equipment purchases and new construction. Through June 30, 2000, the Company has financed its operations primarily through public offerings of common stock, a convertible subordinated notes offering, private placements of redeemable preferred stock, two bank loans, equipment lease lines and a milestone advance totaling approximately $311.6 million. At June 30, 2000, the Company had cash and cash equivalents and short-term investments aggregating approximately $226 million.
We lease our corporate and research and development facilities under an operating lease expiring in 2008. We also have the right to expand the facility and, under certain circumstances, to purchase the facility. We have exercised our right to expand our current facility by 22,500 square feet. We will incur no additional material capital expenditures in connection with this expansion. We expect that rent expense in future years will increase approximately $268,000 per year, commencing in late-2000. We have financed substantially all of our equipment under two bank loans and two master lease
agreements. The first bank loan, which we entered into in February 1997, is for $600,000, is payable in equal monthly installments over 72 months and has a 9.06% interest rate. The second bank loan, which we entered into in December 1998, is for $500,000, is payable in equal monthly installments over 60 months and has a 7.25% interest rate. We have paid off both of the lease agreements. As of July 1, 2000, aggregate outstanding borrowings under these bank loans were approximately $625,000.
Under our agreement with Sanofi-Synthelabo, we are required to make milestone payments upon the achievement of certain development milestones and, until the expiration of the last patent on pleconaril or any related drug, royalty payments on any sales in the United States and Canada of products developed under the agreement. The development milestones include regulatory submissions of New Drug Applications and regulatory approvals in various jurisdictions, however, we may not be able to achieve these milestones. Unless the agreement is earlier terminated, in September 2001 or within 60 days after we file a New Drug Application for pleconaril (whichever occurs sooner), we will be required to pay Sanofi-Synthelabo $900,000.
We entered into an addendum to our development agreement with SELOC France in 1998. Under this addendum, SELOC France has manufactured three validation batches of pleconaril drug substance. We will pay approximately $1,000,000 during the second half of 2000 under this addendum. SELOC France is also assisting us in preparing the pleconaril drug master file and is preparing certain documentation that will be required with our New Drug Applications for pleconaril.
On October 9, 1997, the Company received $1,000,000 from Boehringer Ingelheim Pharmaceuticals, Inc. ("BI") as an advance on a future milestone in connection with a Collaborative Research Agreement (the "Agreement"). The Agreement expired in August 1998. Such amount is due and payable in August 2000. The loan bears interest at 8.5% and is evidenced by a convertible promissory note. If amounts due under the note are not paid as described in the note, BI may convert the then outstanding principal balance and accrued interest thereon into shares of the Company`s common stock based on the last sale price of such common stock on the date immediately prior to the date on which the Company is notified of BI`s intention to convert the promissory note.
We have incurred losses from operations since inception. We expect to incur additional operating losses over at least the next several years. We expect to incur such losses at an increasing rate over at least the next several years primarily due to expected increases in our research and development expenses, further clinical trials and clinical development of our most advanced product candidate, pleconaril (including any significant additional studies for approval in the European Union, if any are required), and milestone payments that may be payable under the terms of our agreement with Sanofi-Synthelabo for pleconaril. Specifically, we expect to increase spending over historical levels for at least the next nine months as we conduct two pivotal clinical trials and several supporting studies for the use of pleconaril for the treatment of viral respiratory infection. Also, we expect to incur expenses for pleconaril marketing and market research activities, our development of a marketing and sales staff and building the requisite infrastructure, and further research and development related to our hepatitis C and RSV disease product candidates. We expect to increase spending over historical levels for at least the next nine months for our hepatitis C and RSV disease product candidates in connection with an anticipated exploratory clinical trial with VP50406 for the treatment of Hepatitis C and the anticipated initiation of safety studies with VP14637 for the treatment of RSV pneumonia. We expect that our spending in the general and administrative areas to remain relatively constant over at least the next six to nine months with such spending in the first half of 2000.
We expect that we will need to raise additional funds to continue our business activities and to further expand our facilities. We may need additional financing to complete all clinical studies, to develop our marketing and sales staffs for pleconaril and to build the requisite infrastructure. We expect that we will need additional financing for the development and required testing of our hepatitis C and RSV disease compounds, and for any other product candidates. To obtain this financing, we intend to access the public or private equity or debt markets or enter into additional arrangements with corporate collaborators to whom we may issue shares of our stock. For example, in connection with our collaboration and license agreement, American Home Products Corporation will purchase our common stock at a market value premium at the time of completion of certain product development stages. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may dilute the ownership of existing stockholders. Collaborative arrangements may require us to grant product development programs or licenses to third parties for products that we might otherwise seek to develop or commercialize ourselves. Additional financing, however, may not be available on acceptable terms from any source. If sufficient additional financing is not available, we may need to delay, reduce or eliminate current research and development programs or other aspects of our business.
Results of Operations
Quarters ended June 30, 2000 and 1999
We earned license fee revenue from our collaboration with Wyeth-Ayerst in the hepatitis C area of $250,000 for the quarter ended June 30, 2000. We had no revenues for the quarter ended June 30, 1999. Research and development expenses decreased to $4,267,971 for the quarter ended June 30, 2000 from $5,233,702 for the quarter ended June 30, 1999. In the second quarter of 2000, the company was preparing to initiate two pivotal trials with pleconaril, the company`s most advanced drug candidate, for the treatment of viral respiratory infection, conducting safety studies with VP50406 for hepatitis C and conducting additional preclinical studies with VP14637 for RSV disease. In the second quarter of 1999, the company was conducting two clinical trials with pleconaril and advancing both the hepatitis C and RSV disease programs. The decrease in expenses in the second quarter of 2000 was primarily due to the fact that clinical studies for pleconaril were ongoing in the second quarter of 1999, and no such studies were conducted in the same period of 2000. Also, the offsetting credit to the receivable due from Wyeth-Ayerst in connection with our hepatitis C collaboration of approximately $1,275,000 has been recorded as a credit to research and development expenses. General and administrative expenses increased to $2,052,367 for the quarter ended June 30, 2000 from $1,240,116 for the quarter ended June 30, 1999. The increase was principally due to an increase in employee related expenses and business development related activities. Interest expense and interest income increased substantially in the second quarter of 2000 compared to the second quarter of 1999. The increases are due to the investing of $180 million convertible subordinated debentures issued in March of 2000 which pay 6% interest per annum. Also, currently the weighted average interest rate that we are earning on our investments is 6.1%. The net loss decreased to $5,389,244 for the quarter ended June 30, 2000 from $6,104,776 for the quarter ended June 30, 1999.
Six-months ended June 30, 2000 and 1999
We earned license fee and milestone revenue from our collaboration with Wyeth-Ayerst in the hepatitis C area of $1,500,000 for the six-month period ended June 30, 2000. We had no revenues for the six-month period ended June 30, 1999. Research and development expenses increased to $10,839,704 for the six- month period ended June 30, 2000 from $10,094,585 for the six-month period ended June 30, 1999. The increase was principally due to the completion of three phase 3 clinical trials of pleconaril, conduct of phase 1 clinical trials of VP50406 for the treatment of hepatitis C and the advancement of our drug candidate for the treatment of RSV disease. Also, the offsetting credit to the receivable due from Wyeth-Ayerst in connection with our hepatitis C collaboration of approximately $1,275,000 has been recorded as a credit to research and development expenses. General and administrative expenses increased to $4,161,500 for the six-month period ended June 30, 2000 from $2,394,332 for the same period of 1999. The increase was principally due to an increase in employee related expenses, pre-marketing expenses related to pleconaril and business development related activities. Interest expense and interest income increased substantially in the six-month period ended June 30, 2000 compared to the same period in 1999. The increases are due to the investing of $180 million convertible subordinated debentures issued in March of 2000 which pay 6% interest per annum. Also, currently the weighted average interest rate that we are earning on our investments is 6.1%. The net loss increased to $12,159,172 for the six-month period ended June 30, 2000 from $11,769,403 for the six-month period ended June 30, 1999.
Recently Issued Accounting Standards
In December 1999, the staff of the Securities and Exchange Commission issued Staff Accounting Bulleting ("SAB") No. 101, Revenue Recognition in Financial Statements ("SAB 101"). SAB 101 summarizes certain of the staff`s views in applying generally accepted accounting principles to revenue recognition in financial statements, including the recognition of non-refundable fees received upon entering into arrangements. We are in the process of evaluating this SAB and the effect it will have on our financial statements and current revenue recognition policy.
--------------------------------------------------------------------------------
© Copyright 1995-1999 EDGAR Online, Inc. All rights reserved.
High,
Endspurt an der Nasdaq.
Der Viropharma Schlusskurs:
VIROPHARMA INC
VPHM.NAS/WKN 928241108
Datum Letzter Zeit Differenz
11.08.00 19,50 21:59 +8,71%
Eröffnungskurs 18,09
Hoch 19,50
Tief 17,81
Schlußkurs 17,94 (10.08.00 21:59)
Kassakurs n/a
Volumen 48,000
EUR 671,638
Ganz schön anstrengend,
dem Nasdaq Kurs hinterherzuhecheln!
Gute Nacht
durt
Endspurt an der Nasdaq.
Der Viropharma Schlusskurs:
VIROPHARMA INC
VPHM.NAS/WKN 928241108
Datum Letzter Zeit Differenz
11.08.00 19,50 21:59 +8,71%
Eröffnungskurs 18,09
Hoch 19,50
Tief 17,81
Schlußkurs 17,94 (10.08.00 21:59)
Kassakurs n/a
Volumen 48,000
EUR 671,638
Ganz schön anstrengend,
dem Nasdaq Kurs hinterherzuhecheln!
Gute Nacht
durt
High,
Der Kursverlauf sieht doch ganz erfreulich aus!
Schönes Wochenende!
durt
VIROPHARMA INC
VPHM.NAS/WKN 928241108
Datum Letzter Zeit Differenz
18.08.00 20,88 18.08. +1,83%
Eröffnungskurs 20,53
Hoch 20,88
Tief 20,25
Schlußkurs 20,50 (17.08.00 21:59)
Kassakurs n/a
Volumen 134,900
EUR 2.46 Mio.
Details
ISIN 92824110
Währung US Dollar
Wertpapiertyp Aktie
Börse Nasdaq
Dividende n/a
Dividendenrendite n/a
Dividendendatum -
vorh. Dividendendatum -
Nächster Quartalsbericht -
Performance 3mo +38,98%
- Vs. benchmark +35,88%
KGV n/a
Gewinn pro Aktie, EUR n/a
200 Tage gleitender Durchschnitt 33,82
Der Kursverlauf sieht doch ganz erfreulich aus!
Schönes Wochenende!
durt
VIROPHARMA INC
VPHM.NAS/WKN 928241108
Datum Letzter Zeit Differenz
18.08.00 20,88 18.08. +1,83%
Eröffnungskurs 20,53
Hoch 20,88
Tief 20,25
Schlußkurs 20,50 (17.08.00 21:59)
Kassakurs n/a
Volumen 134,900
EUR 2.46 Mio.
Details
ISIN 92824110
Währung US Dollar
Wertpapiertyp Aktie
Börse Nasdaq
Dividende n/a
Dividendenrendite n/a
Dividendendatum -
vorh. Dividendendatum -
Nächster Quartalsbericht -
Performance 3mo +38,98%
- Vs. benchmark +35,88%
KGV n/a
Gewinn pro Aktie, EUR n/a
200 Tage gleitender Durchschnitt 33,82
High,
Guter Kursverlauf von Viropharma !
Hier die Schlusskurse und
weitere Informationen :
Symbol VPHM Volume 315,400
Last Trade 24.19 !!!
Net Change 3.06
Yesterday`s Close 21.13
Today`s Open 21.50 Market Cap (000s) $367,311
Time of Last Trade 4:02:00 PM EST Earn/Shr -2.62
Highs & Lows
Performance
Today`s High 24.38 Today`s % Change 14.50% !!!
52-Week High 111.62 This Week`s % Change 15.87%
Today`s Low 21.50 This Month`s % Change 29.87%
52-Week Low 10.5 This Year`s % Change -34.74%
----------------------------------------------------------------
Princeton, New Jersey, Aug. 22 (Bloomberg Data) -- ViroPharma Inc. (VPHM US) was reiterated ``strong buy`` by analyst Carolyn Pratt at Needham & Co. The price target is $43.
--------------------------------------------------------------------
ViroPharma Incorporated Appoints Michel de Rosen President
8/22/00 5:00:00 AM
Source: PR Newswire
And Chief Executive Officer
EXTON, Pa., Aug. 22 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today the appointment of Michel de Rosen as president and chief executive officer. Claude Nash, ViroPharma`s founder and former president and chief executive officer, will remain chairman of the board of directors. The key addition of Michel de Rosen to the management team will further the growth of ViroPharma into a fully-integrated pharmaceutical company focused on developing innovative products to treat people who suffer from viral disease.
"ViroPharma has reached a critical point in its evolution," said Claude Nash. "I wanted my successor to be a visionary with pharmaceutical business experience and the passion to lead ViroPharma to the next level. Michel has those qualities. He will be a tremendous asset to our company and I am delighted that he`s decided to join us."
"ViroPharma is a young company that I have come to know well over the last few months as a member of the board of directors," said Michel de Rosen. "I am committed to advancing pleconaril toward commercialization, maximizing the potential of our other product candidates and enhancing our product portfolio so we can expand our reach into the antiviral market. I believe we will succeed because of the entrepreneurial spirit of the company -- inspired and sustained by Claude Nash -- the quality of ViroPharma`s pipeline and partnerships with leading pharmaceutical companies and its highly motivated people."
Michel de Rosen joined the board of directors of ViroPharma in May 2000. He spent several years as the chairman of Rhone-Poulenc Pharma and chairman and chief executive officer of Rhone-Poulenc Rorer (now Aventis Pharma). During his tenure at Rhone-Poulenc Rorer, Mr. de Rosen contributed significantly to rejuvenating and focusing the company`s product portfolio, transforming its research and development, restructuring its business operations, and as a result, growing the company`s revenue and income.
ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The Company is focused on drug development and discovery activities for viral diseases, including viral respiratory infection (VRI), hepatitis C and respiratory syncytial virus disease.
This press release contains forward-looking statements, including statements relating to the Company`s ongoing efforts to obtain regulatory approval for and commercialize its product candidates. Certain of ViroPharma`s product candidates, including pleconaril, currently are in clinical trials. There can be no assurance that planned or ongoing clinical trials can be successfully concluded or concluded in accordance with the Company`s anticipated schedule. The conduct of clinical trials and acquiring regulatory approval for investigational pharmaceutical products are subject to risks and uncertainties. Neither the FDA nor any other regulatory authority has approved pleconaril or any of ViroPharma`s other product candidates for commercialization. There can be no assurance that FDA or other regulatory authority approval for pleconaril or any other product candidate under development by ViroPharma will be granted on a timely basis or at all. Even if approved, there can be no assurance that pleconaril will achieve market acceptance. These factors, and other factors that could cause future results to differ materially from the expectations expressed in this press release, include, but are not limited to, those described in ViroPharma`s most recent Registration Statement on Form S-3 filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.
SOURCE ViroPharma Incorporated
--------------------------------------------------------------------
ViroPharma Form S-3 Related to Its Subordinated Convertible
8/21/00 7:10:00 AM
Source: PR Newswire
Notes
EXTON, Pa., Aug. 21 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Securities and Exchange Commission has declared its Registration Statement on Form S-3 (File No. 333-37960) effective as of August 21, 2000, registering the resale of its 6% Subordinated Convertible Notes due March 1, 2007 and of shares of its common stock issuable upon conversion thereof by certain holders of the Notes, pursuant to the Registration Rights Agreement that ViroPharma entered into when the Notes were issued. No securities are being issued or offered by ViroPharma in connection with this registration statement. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The Company is focused on drug development and discovery activities in viral diseases including viral respiratory infection (VRI), hepatitis C and RSV disease.
SOURCE ViroPharma Incorporated
Gute Nacht
durt
Guter Kursverlauf von Viropharma !
Hier die Schlusskurse und
weitere Informationen :
Symbol VPHM Volume 315,400
Last Trade 24.19 !!!
Net Change 3.06
Yesterday`s Close 21.13
Today`s Open 21.50 Market Cap (000s) $367,311
Time of Last Trade 4:02:00 PM EST Earn/Shr -2.62
Highs & Lows
Performance
Today`s High 24.38 Today`s % Change 14.50% !!!
52-Week High 111.62 This Week`s % Change 15.87%
Today`s Low 21.50 This Month`s % Change 29.87%
52-Week Low 10.5 This Year`s % Change -34.74%
----------------------------------------------------------------
Princeton, New Jersey, Aug. 22 (Bloomberg Data) -- ViroPharma Inc. (VPHM US) was reiterated ``strong buy`` by analyst Carolyn Pratt at Needham & Co. The price target is $43.
--------------------------------------------------------------------
ViroPharma Incorporated Appoints Michel de Rosen President
8/22/00 5:00:00 AM
Source: PR Newswire
And Chief Executive Officer
EXTON, Pa., Aug. 22 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today the appointment of Michel de Rosen as president and chief executive officer. Claude Nash, ViroPharma`s founder and former president and chief executive officer, will remain chairman of the board of directors. The key addition of Michel de Rosen to the management team will further the growth of ViroPharma into a fully-integrated pharmaceutical company focused on developing innovative products to treat people who suffer from viral disease.
"ViroPharma has reached a critical point in its evolution," said Claude Nash. "I wanted my successor to be a visionary with pharmaceutical business experience and the passion to lead ViroPharma to the next level. Michel has those qualities. He will be a tremendous asset to our company and I am delighted that he`s decided to join us."
"ViroPharma is a young company that I have come to know well over the last few months as a member of the board of directors," said Michel de Rosen. "I am committed to advancing pleconaril toward commercialization, maximizing the potential of our other product candidates and enhancing our product portfolio so we can expand our reach into the antiviral market. I believe we will succeed because of the entrepreneurial spirit of the company -- inspired and sustained by Claude Nash -- the quality of ViroPharma`s pipeline and partnerships with leading pharmaceutical companies and its highly motivated people."
Michel de Rosen joined the board of directors of ViroPharma in May 2000. He spent several years as the chairman of Rhone-Poulenc Pharma and chairman and chief executive officer of Rhone-Poulenc Rorer (now Aventis Pharma). During his tenure at Rhone-Poulenc Rorer, Mr. de Rosen contributed significantly to rejuvenating and focusing the company`s product portfolio, transforming its research and development, restructuring its business operations, and as a result, growing the company`s revenue and income.
ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The Company is focused on drug development and discovery activities for viral diseases, including viral respiratory infection (VRI), hepatitis C and respiratory syncytial virus disease.
This press release contains forward-looking statements, including statements relating to the Company`s ongoing efforts to obtain regulatory approval for and commercialize its product candidates. Certain of ViroPharma`s product candidates, including pleconaril, currently are in clinical trials. There can be no assurance that planned or ongoing clinical trials can be successfully concluded or concluded in accordance with the Company`s anticipated schedule. The conduct of clinical trials and acquiring regulatory approval for investigational pharmaceutical products are subject to risks and uncertainties. Neither the FDA nor any other regulatory authority has approved pleconaril or any of ViroPharma`s other product candidates for commercialization. There can be no assurance that FDA or other regulatory authority approval for pleconaril or any other product candidate under development by ViroPharma will be granted on a timely basis or at all. Even if approved, there can be no assurance that pleconaril will achieve market acceptance. These factors, and other factors that could cause future results to differ materially from the expectations expressed in this press release, include, but are not limited to, those described in ViroPharma`s most recent Registration Statement on Form S-3 filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.
SOURCE ViroPharma Incorporated
--------------------------------------------------------------------
ViroPharma Form S-3 Related to Its Subordinated Convertible
8/21/00 7:10:00 AM
Source: PR Newswire
Notes
EXTON, Pa., Aug. 21 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Securities and Exchange Commission has declared its Registration Statement on Form S-3 (File No. 333-37960) effective as of August 21, 2000, registering the resale of its 6% Subordinated Convertible Notes due March 1, 2007 and of shares of its common stock issuable upon conversion thereof by certain holders of the Notes, pursuant to the Registration Rights Agreement that ViroPharma entered into when the Notes were issued. No securities are being issued or offered by ViroPharma in connection with this registration statement. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The Company is focused on drug development and discovery activities in viral diseases including viral respiratory infection (VRI), hepatitis C and RSV disease.
SOURCE ViroPharma Incorporated
Gute Nacht
durt
High,
Sehr schöner Kursverlauf !
Geneigte Leser, wo seht Ihr
denn das Kursziel ?
Gute Nacht
durt
VIROPHARMA INC DL-,01 (Frankfurt:903906.F) - Mehr Infos: N/A
Letzter Kurs
Aug 28 · 34,00 Veränderung
+2,10 (+6,58%) Vorheriger Schlußkurs
31,90
Klein: [ 1T | 5T | keine ]
Groß: [ 1T | 5T ]
Tages-Kursspanne
33,05 - 34,20 Geldkurs
33,60 Briefkurs
34,20 Eröffnungskurs
33,20
Volumen
9.259 EpA
N/A KGV
N/A Mkt Kapitalisierung
N/A
Sehr schöner Kursverlauf !
Geneigte Leser, wo seht Ihr
denn das Kursziel ?
Gute Nacht
durt
VIROPHARMA INC DL-,01 (Frankfurt:903906.F) - Mehr Infos: N/A
Letzter Kurs
Aug 28 · 34,00 Veränderung
+2,10 (+6,58%) Vorheriger Schlußkurs
31,90
Klein: [ 1T | 5T | keine ]
Groß: [ 1T | 5T ]
Tages-Kursspanne
33,05 - 34,20 Geldkurs
33,60 Briefkurs
34,20 Eröffnungskurs
33,20
Volumen
9.259 EpA
N/A KGV
N/A Mkt Kapitalisierung
N/A
Trading Spotlight
Charttechnisch ausgebrochen. Aber kann mir mal einer ganz knapp das englische Zusammenfassen? Danke vorab.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +11,38 | |
| -1,86 | |
| -0,81 | |
| +1,66 | |
| +0,60 | |
| +0,56 | |
| +0,07 | |
| -0,08 | |
| +0,12 | |
| +0,40 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 133 | ||
| 82 | ||
| 52 | ||
| 32 | ||
| 31 | ||
| 27 | ||
| 26 | ||
| 14 | ||
| 13 | ||
| 10 |
